Merck & Co's Keytruda blockbuster immunotherapy could have yet another use, after it significantly boosted survival in patients with untreated squamous non-small cell lu
First quarter results from AstraZeneca have disappointed investors, sending shares down on the London Stock Exchange, as the UK firm continued to feel the effects of patent losses on key dr
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.